• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于预测乳腺癌术前化疗后未达到病理完全缓解患者无病生存的风险评分。

A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer.

作者信息

Colleoni M, Bagnardi V, Rotmensz N, Dellapasqua S, Viale G, Pruneri G, Veronesi P, Torrisi R, Luini A, Intra M, Galimberti V, Montagna E, Goldhirsch A

机构信息

Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Milan, Italy.

出版信息

Ann Oncol. 2009 Jul;20(7):1178-84. doi: 10.1093/annonc/mdn747. Epub 2009 Feb 13.

DOI:10.1093/annonc/mdn747
PMID:19218304
Abstract

BACKGROUND

We aimed to predict disease-free survival (DFS) in patients who failed to achieve a pathologic complete remission (pCR) after preoperative chemotherapy (PC).

PATIENTS AND METHODS

Data from 577 patients treated with PC and operated at the European Institute of Oncology (EIO) were used to develop a nomogram using Cox proportional hazards regression model based on both categorical (pT, positive nodes, human epidermal growth factor receptor 2 (HER2) status, vascular invasion) and continuous histological variables (estrogen receptors and Ki-67 expression) at surgery. The nomogram was tested on a second patient cohort (343 patients) treated in other institutions and subsequently operated at the EIO.

RESULTS

The nomogram for DFS based on both categorical and continuous variables had good discrimination in the training and the validation sets (concordance indices 0.73, 0.67).

CONCLUSION

The use of a nomogram based on the degree of selected histopathological variables can predict DFS and might help in the adjuvant therapeutic algorithm design.

摘要

背景

我们旨在预测术前化疗(PC)后未达到病理完全缓解(pCR)的患者的无病生存期(DFS)。

患者与方法

来自欧洲肿瘤研究所(EIO)接受PC治疗并接受手术的577例患者的数据,用于基于手术时的分类变量(pT、阳性淋巴结、人表皮生长因子受体2(HER2)状态、血管侵犯)和连续组织学变量(雌激素受体和Ki-67表达),使用Cox比例风险回归模型制定列线图。该列线图在其他机构治疗并随后在EIO接受手术的第二个患者队列(343例患者)中进行了测试。

结果

基于分类变量和连续变量的DFS列线图在训练集和验证集中具有良好的区分度(一致性指数分别为0.73、0.67)。

结论

使用基于所选组织病理学变量程度的列线图可以预测DFS,并可能有助于辅助治疗算法的设计。

相似文献

1
A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer.一种用于预测乳腺癌术前化疗后未达到病理完全缓解患者无病生存的风险评分。
Ann Oncol. 2009 Jul;20(7):1178-84. doi: 10.1093/annonc/mdn747. Epub 2009 Feb 13.
2
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.预测乳腺癌术前化疗后病理完全缓解和无转移生存期的列线图。
J Clin Oncol. 2005 Nov 20;23(33):8331-9. doi: 10.1200/JCO.2005.01.2898.
3
Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.食管鳞状细胞癌患者接受食管切除术后辅助化疗,针对此前未接受过治疗患者的预后列线图。
Jpn J Clin Oncol. 2016 Apr;46(4):336-43. doi: 10.1093/jjco/hyv206. Epub 2016 Jan 26.
4
Development and Validation of a Nomogram for Individually Predicting Pathologic Complete Remission After Preoperative Chemotherapy in Chinese Breast Cancer: A Population-Based Study.基于人群的研究:建立并验证中国人乳腺癌患者新辅助化疗后病理完全缓解的个体化预测列线图
Clin Breast Cancer. 2020 Dec;20(6):e682-e694. doi: 10.1016/j.clbc.2020.06.010. Epub 2020 Jul 8.
5
A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer.基于 Ki-67 表达、甾体激素受体状态和化疗疗程数的列线图预测乳腺癌新辅助化疗后病理完全缓解。
Eur J Cancer. 2010 Aug;46(12):2216-24. doi: 10.1016/j.ejca.2010.04.008. Epub 2010 May 13.
6
Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.新辅助化疗前后Ki67表达在HR阴性乳腺癌中的预后价值
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.
7
Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.用于预测接受新辅助全身治疗的HER2阳性乳腺癌病理完全缓解的列线图。
Br J Cancer. 2017 Feb 14;116(4):509-514. doi: 10.1038/bjc.2016.444. Epub 2017 Jan 12.
8
Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors.两种列线图预测乳腺癌新辅助化疗病理完全缓解的比较:HER2 阳性肿瘤需要特定预测因子的证据。
Breast Cancer Res Treat. 2012 Apr;132(2):601-7. doi: 10.1007/s10549-011-1897-0. Epub 2011 Dec 9.
9
Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.CS-IHC4评分与预测激素受体阳性乳腺癌复发的列线图的验证与比较
Oncology. 2014;86(5-6):279-88. doi: 10.1159/000362281. Epub 2014 Jun 4.
10
Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.曲妥珠单抗术前化疗后HER2阳性乳腺癌病理完全缓解的预测因素:特定预测指标的开发及其效用的决策曲线分析研究
Breast Cancer Res Treat. 2017 Jan;161(1):73-81. doi: 10.1007/s10549-016-4040-4. Epub 2016 Nov 2.

引用本文的文献

1
Machine learning-based prediction of disease-free survival in breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy: a retrospective multicenter cohort study.基于机器学习预测新辅助化疗后非病理完全缓解的乳腺癌患者无病生存期:一项回顾性多中心队列研究
Am J Cancer Res. 2025 Jun 15;15(6):2482-2499. doi: 10.62347/MHSV3723. eCollection 2025.
2
The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.中性粒细胞与淋巴细胞比值对接受新辅助化疗的乳腺癌患者总生存和病理完全缓解的预测价值
Front Oncol. 2023 Jan 16;12:1065606. doi: 10.3389/fonc.2022.1065606. eCollection 2022.
3
Stratification of Prognosis by Biological Features Following Neoadjuvant Chemotherapy in Luminal Breast Cancer.
新辅助化疗后 Luminal 型乳腺癌的生物学特征预后分层。
In Vivo. 2022 Mar-Apr;36(2):859-864. doi: 10.21873/invivo.12774.
4
Development and validation of a risk stratification nomogram for predicting prognosis in bone metastatic breast cancer: A population-based study.基于人群的研究:用于预测骨转移乳腺癌患者预后的风险分层列线图的开发和验证。
Medicine (Baltimore). 2021 Feb 12;100(6):e24751. doi: 10.1097/MD.0000000000024751.
5
Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.基质金属蛋白酶(MMP)-9 在三阴性乳腺癌新辅助化疗中的预测和预后价值。
BMC Cancer. 2018 Sep 21;18(1):909. doi: 10.1186/s12885-018-4822-7.
6
Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy.新辅助化疗治疗的乳腺癌患者无病生存预测及风险分层预后模型的建立与外部验证
Cancer Manag Res. 2018 Aug 1;10:2347-2356. doi: 10.2147/CMAR.S171129. eCollection 2018.
7
Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy.新辅助化疗治疗乳腺癌长期获益的临床病理预测因素
World J Clin Oncol. 2018 Apr 10;9(2):33-41. doi: 10.5306/wjco.v9.i2.33.
8
Aberrant expression through 3'UTR alternative polyadenylation in breast cancers.乳腺癌中通过3'非翻译区可变聚腺苷酸化的异常表达。
FEBS Open Bio. 2018 Jan 26;8(3):332-338. doi: 10.1002/2211-5463.12364. eCollection 2018 Mar.
9
Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin.每周紫杉醇联合卡铂新辅助化疗前后三阴性乳腺癌中Ki-67表达的价值
Sci Rep. 2016 Jul 18;6:30091. doi: 10.1038/srep30091.
10
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.新辅助化疗多柔比星/环磷酰胺序贯多西他赛后腋窝淋巴结比率对乳腺癌的预后价值:一项多中心回顾性队列研究。
Cancer Res Treat. 2016 Oct;48(4):1373-1381. doi: 10.4143/crt.2015.475. Epub 2016 Mar 23.